Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes

Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes

(2012) Michael Horowitz et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Short-term effects of liraglutide on visceral fat adiposity, appetite, and food preference: a pilot study of obese Japanese patients with type 2 diabetes

(2011) Kana Inoue et al.   Cardiovascular Diabetology

Postprandial hyperlipidemia, endothelial dysfunction and cardiovascular risk: focus on incretins

(2011) Sameer Ansar et al.   Cardiovascular Diabetology

Benefits of Modest Weight Loss in Improving Cardiovascular Risk Factors in Overweight and Obese Individuals With Type 2 Diabetes

(2011) R. R. Wing et al.   DIABETES CARE

Association between Body-Mass Index and Risk of Death in More Than 1 Million Asians

(2011) Wei Zheng et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cardiovascular Comorbidities of Type 2 Diabetes Mellitus: Defining the Potential of Glucagonlike peptide–1-Based Therapies

(2010) Robert Chilton et al.   AMERICAN JOURNAL OF MEDICINE

Effect of alogliptin, pioglitazone and glargine on pancreatic β-cells in diabetic db/db mice

(2010) Satoshi Kawashima et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Elevated circulating levels of an incretin hormone, glucagon-like peptide-1, are associated with metabolic components in high-risk patients with cardiovascular disease

(2010) Minako Yamaoka-Tojo et al.   Cardiovascular Diabetology

Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes

(2010) Y. Seino et al.   CURRENT MEDICAL RESEARCH AND OPINION

Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes

(2009) K. Kaku et al.   DIABETES OBESITY & METABOLISM

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

(2009) D. Russell-Jones et al.   DIABETOLOGIA

The Extrapancreatic Effects of Glucagon-Like Peptide-1 and Related Peptides

(2009) Rania Abu-Hamdah et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study

(2009) Arne Astrup et al.   LANCET

Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes

(2008) Y. Seino et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Near normalisation of blood glucose improves the potentiating effect of GLP-1 on glucose-induced insulin secretion in patients with type 2 diabetes

(2008) P. V. Højberg et al.   DIABETOLOGIA

Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes

(2008) P. V. Højberg et al.   DIABETOLOGIA